SCHEDULE: Biodesix Stakeholder Adjusts Holdings
Beneficial Ownership Filing Amendment
Jack W. Schuler and associated entities have amended their Schedule 13D filing, detailing adjustments to their beneficial ownership of Biodesix, Inc. common stock.
Summary
- This filing is an amendment (Amendment No. 11) to a Schedule 13D concerning Biodesix, Inc. common stock.
- The filing is made by Jack W. Schuler, the Jack W. Schuler Living Trust, and the Jack W. Schuler 2026 GRAT.
- As of November 12, 2026, Jack W. Schuler may be deemed to beneficially own 2,476,545 shares, representing approximately 22.3% of the outstanding shares.
- This ownership includes shares held directly, through the Trust, through the 2026 GRAT, and shares Mr. Schuler has the right to acquire within 60 days.
- Recent transactions include transfers between trusts and open market purchases by Mr. Schuler through the Trust in August and November 2026.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting ongoing beneficial ownership adjustments and strategic share accumulation by a significant stakeholder, without immediate negative indicators.
Positives
- Jack W. Schuler continues to demonstrate significant beneficial ownership (22.3%) in Biodesix, Inc., indicating sustained confidence.
- Strategic adjustments in share allocation between trusts (Jack W. Schuler Living Trust and Jack W. Schuler 2026 GRAT) suggest organized management of holdings.
- Open market purchases in August and November 2026 show active accumulation of shares, potentially signaling a belief in future value.
Negatives
- The filing details a cessation of beneficial ownership by the Jack W. Schuler 2025 GRAT as of March 25, 2026, indicating a shift in holding structure.
Risks
- The filing does not explicitly mention any new risks or changes to existing risk factors for Biodesix, Inc.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from the company. It primarily details current beneficial ownership and recent transactions by a significant stakeholder.
Management Comments
- No direct management comments from Biodesix, Inc. are included in this filing; it is an update from a beneficial owner.
Industry Context
StockSavvy.ai notes that Schedule 13D filings are common for significant investors accumulating or adjusting stakes in public companies. This filing indicates continued active management of a substantial position in Biodesix, Inc. by Jack W. Schuler and his associated entities, which is typical in the biotechnology or healthcare sectors where ownership concentration can be a factor.
Related Party Transactions
- Transfers of shares between Jack W. Schuler Living Trust and Jack W. Schuler 2026 GRAT for no additional consideration.
Stakeholder Impact
- Shareholders: The continued significant stake and active management by Jack W. Schuler may influence market perception and potential future corporate actions.
- Creditors: No direct impact mentioned.
- Employees: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Customers: No direct impact mentioned.
Next Steps
- The filing does not outline specific next steps for the company or the reporting persons beyond the ongoing management of beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 2020-11-09 | Date of the Initial Schedule 13D filing. |
| 2025-03-25 | Date the Jack W. Schuler 2025 GRAT ceased to beneficially own any Shares. |
| 2026-04-01 | Date 1,800,000 Shares were transferred from the Trust to the 2026 GRAT. |
| 2026-08-10 | Date Mr. Schuler, through the Trust, purchased 13,900 Shares in the open market. |
| 2026-08-11 | Date Mr. Schuler, through the Trust, purchased 13,700 Shares in the open market. |
| 2026-08-12 | Date Mr. Schuler, through the Trust, purchased 15,000 Shares in the open market. |
| 2026-10-30 | Date as of which 11,088,511 Shares were outstanding, as reported in the Issuer's Form 10-Q. |
| 2026-11-05 | Date of filing of Issuer's quarterly report on Form 10-Q. |
| 2026-11-10 | Date Mr. Schuler, through the Trust, purchased 100,000 Shares in the open market. |
| 2026-11-12 | Date of the filing of Amendment No. 11 to Schedule 13D and the Joint Filing Agreement. |
Keywords
Biodesix, Schedule 13D, Beneficial Ownership, Shareholder, Investment, Securities, Trust, GRAT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.